FDA Panel Opposes “Boxed” Warning For Increased Suicidality In Anti-Epileptic Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee agrees anti-epileptics demonstrate a risk signal for suicidality, but sees potential for more harm than good in adding black box.
You may also be interested in...
Antiepileptics May Get Class Suicide Warning Though Classwide Risk Was Not Seen
Three of the 11 drugs studied did not exhibit a strong suicidality signal, but FDA says the data merit a “black box” warning for all.
FDA Extends Antidepressant “Black Box” Warning On Suicidality To Young Adults
Updated labeling, however, also adds language about the risks of depression to emphasize that antidepressants have value.
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.